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Abstract: An area of therapeutic interest in cancer biology and treatment is targeting the cancer stem cell, more appropriately referred to 
as the cancer initiating cell (CIC). CICs comprise a subset of hierarchically organized, rare cancer cells with the ability to initiate cancer 
in xenografts in genetically modified murine models. CICs are thought to be responsible for tumor onset, self-renewal/maintenance, mu-
tation accumulation and metastasis. CICs may lay dormant after various cancer therapies which eliminate the more rapidly proliferating 
bulk cancer (BC) mass. However, CICs may remerge after therapy is discontinued as they may represent cells which were either intrinsi-
cally resistant to the original therapeutic approach or they have acquired mutations which confer resistance to the primary therapy. In ex-
perimental mouse tumor transplant models, CICs have the ability to transfer the tumor to immunocompromised mice very efficiently 
while the BCs are not able to do so as effectively. Often CICs display increased expression of proteins involved in drug resistance and 
hence they are intrinsically resistant to many chemotherapeutic approaches. Furthermore, the CICs may be in a suspended state of prolif-
eration and not sensitive to common chemotherapeutic and radiological approaches often employed to eliminate the rapidly proliferating 
BCs. Promising therapeutic approaches include the targeting of certain signal transduction pathways (e.g., RAC, WNT, PI3K, PML) with 
small molecule inhibitors or targeting specific cell-surface molecules (e.g., CD44), with effective cytotoxic antibodies. The existence of 
CICs could explain the high frequency of relapse and resistance to many currently used cancer therapies. New approaches should be de-
veloped to effectively target the CIC which could vastly improve cancer therapies and outcomes. This review will discuss recent concepts 
of targeting CICs in certain leukemia models. 
Keywords: Therapeutic sensitivity, targeted therapy, PI3K, PTEN, Akt, mTOR. 
OVERVIEWS OF CANCER, STEM CELLS AND CANCER 
INITIATING CELLS (CICS) 
 Cancer is a complex, multigenetic disorder characterized by 
uncontrolled proliferation, blockage in cellular differentiation, and 
metastases. Previously cancer biologists explained the process of 
cancer initiation and progression by means of a clonal/stochastic 
model. According to this model, a cell or a group of cells become 
tumorigenic after an initial somatic or germinal mutation, and sub-
sequent series of genetic/epigenetic mutations, leading to prolifera-
tive and survival advantage of certain cell clones. This theory hy-
pothesizes that the predominant clones with the capacity to produce 
identical neoplastic cells engender the tumor with the ability to 
produce initial neoplastic cells which maintain the tumor and capa-
bility to initiate other tumors after transplantation [1]. This clonal 
evolution model assumed that cancer was comprised of a clone or 
group of clones with similar growth rates that displayed a homoge-
nous morphological pattern. Moreover this theory predicted that all 
cancer cells could randomly initiate and propagate the tumor by 
themselves [2-3]. However, this model has two fundamental limita-
tions. First, not all neoplastic cells in a given tumor are homoge-
nous and the differentiation patterns in tumors can be distinguished. 
Second, the clonal/stochastic model implies that every cancer cell 
could initiate a tumor. However, this tenant was not consistent with 
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the observation that a large number of cells were required to trans-
fer a tumor.  
 Before we discuss cancer stem cells, we need to first very 
briefly describe normal stem cells. Stem cells are often defined by 
their potential for self-renewal and by their ability to proliferate and 
differentiate into diverse cell types. Since this review will cover in 
detail leukemia CICs, we will discuss hematopoietic stem cells 
(HSC). Normal HSCs have been characterized over the past 50 
years [4]. HSCs comprise a very small, but essential, sub-
population of the total hematopoietic cell component, making up 
less than 0.01% of cells in the bone marrow of a normal individual 
[5]. Stem cells are also present in other tissue types (e.g., breast, 
prostate and other cell types), but often not as well characterized as 
HSCs. 
 A critical breakthrough in cancer research over the past 15 
years has been the discovery of cancer initiating cells (CICs). These 
cells are also sometimes referred to as cancer stem cells; however, 
the adjective stem is now more frequently replaced with initiating 
as they lack certain key properties which true stem cells possess. 
Furthermore, the CICs may have suffered critical mutations which 
hopefully the “normal” stem cell lacks. The CIC concept entails 
that cancer initiation and propagation are driven by small subpopu-
lations of cells displaying stem cell-like properties, such as the ca-
pability of self-renewal, asymmetric cell division and differentia-
tion. CICs may arise from a normal stem cell and undergo epige-
netic changes. CICs are likely capable of differentiating into a phe-
notypically diverse progeny which may ultimately form subsets of 
non-tumorigenic bulk cancer (BC) which have a limited capacity to 
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divide and survive. CICs are resistant to conventional cytotoxic 
treatments. This resistance contributes tumor metastases and re-
lapse. Conventional anti-tumor treatments, such as polychemother-
apy, can only act on more mature BCs whereas CICs are normally 
resistant to these approaches, often due to the overexpression of 
proteins involved in drug resistance (see below) and their low pro-
liferation rate.  
 CICs have been identified over the last decade in diverse cancer 
types and some of the key genes and signaling pathways responsi-
ble for their important cancer initiating and invasive properties are 
beginning to be elucidated [6-12].  
 Over the last 15 years, the CIC theory of cancer evolution has 
been proposed. This alternative model assumes the existence of a 
hierarchical order where a tissue-specific, programmed or repro-
grammed cell, the so-called CIC, acquires or retains the properties 
of self-renewal, multi-lineage differentiation, and most importantly, 
tumor initiation, both in vitro and in vivo [13]. This population of 
rare cells is the only one capable of initiating and maintaining the 
tumor, thus allowing cancer diffusion to other organs, or cancer 
transplantation into other living beings, typically mice. According 
to the CIC model, the BCs would be transient amplifying cells and 
mature cells with limited or no ability whatsoever to initiate and/or 
maintain the tumor [14].  
 Such a model of cell organization, which is the basis for the 
definition of a CIC, is not new. It is thought to be the rule during 
embryonic development, and in various adult tissues, for example, 
in high-turnover tissues such as the lining epithelia and the bone 
marrow, with a hierarchical system based on the existence of a stem 
cell that displays self-renewal activity through asymmetric cell 
division and multi-potential differentiation ability. Thus, the CIC 
model of tumor biology entails the existence of a hierarchy of cells 
within a cancer that represents a caricature of cell hierarchies exist-
ing in normal tissues. CICs are at the apex of such hierarchy [15].  
 The fundamental clinical implications of a tumorigenic hierar-
chy within a tumor become apparent when considering that anti-
cancer therapies are not selected for their discriminatory ability to 
target CICs. Therefore, if a given therapy fails to eliminate all the 
self-renewing CICs, residual surviving CICs will be able to repopu-
late the disease, causing tumor relapse [16].  
 Although mounting evidence supports the CIC model, it is im-
portant to be aware of a number of drawbacks that should be fully 
addressed. First, there is no evidence whatsoever that carcinogenic 
cells are significantly different from non-carcinogenic cells as a 
result of epigenetic rather than genetic changes [17-19]. Our current 
understanding of tumorigenesis is that cumulative mutations de-
velop during cancer progression [20]. Therefore, at least in theory, 
these changes could result in more than one CIC population capable 
of maintaining and propagating the tumor, by developing a self-
renewal program. This theory is supported by the observation that 
there are neoplasias (for example pancreatic carcinoma or acute 
lymphoblastic leukemia, [ALL]) in which more than one pheno-
typically distinct population can initiate tumors in vivo [21]. Like-
wise, in acute myelogenous leukemia (AML), CICs (AML-CICs) 
undergo clonal evolution [22], while in chronic myelogenous leu-
kemia (CML) one or more Imatinib-resistant CML-CIC subclones 
may be selected during therapy and progress to blast crisis (see 
below) [23-24]. 
 Furthermore, there is evidence for chromosomal instability in 
the CICs derived from human metastatic colon carcinoma [25]. 
Based on these findings, a new CIC hypothesis should probably 
include both the stochastic/clonal evolution and the CIC hierarchi-
cal components [26].  
 Second, a lineage-committed progenitor cell can also function 
like a CIC by acquiring self-renewal, as demonstrated in both hu-
man CML [27] and a murine model of acute promyelocytic leuke-
mia (APL) [28]. Third, the premise that transplanted CICs can re-
capitulate the heterogeneity of the tumor from which they origi-
nated is usually based on limited analyses of a few surface markers 
[29]. It remains to be determined if there is also genetic heterogene-
ity within the primary tumor, that is not present after CIC 
xenotransplantation. Thus, it may be that the functional and pheno-
typic diversity within these neoplasias are underestimated. Fourth, a 
fundamental issue in the CIC model is related to the very low num-
ber of the CICs. The gold standard for estimating and quantifying 
CICs in vivo is limiting dilution followed by transplantation in Non 
Obese Diabetic/Severe Combined Immunodeficient (NOD/SCID) 
mice. This method could lead to underestimating the frequency of 
CICs in some cancer types, such as AML and melanomas, as seed-
ing and tumor development in animals vary widely from case to 
case [30-33].  
 It has been proposed that xenotransplantation in animals which 
are not entirely immunodeficient may lead to underestimating the 
number of CICs in vivo. This may also depend on the fact that the 
microenvironment or the CIC niches (which clearly support CIC 
functions) are species-specific and often tumor-specific [34]. 
Hence, the mouse microenvironment/niche may differ in many 
aspects from the cancer microenvironment/niche sustaining CICs in 
the natural (human) host. Moreover, murine microenvironment/ 
niche receptors and cytokines may not necessarily cross-interact in 
all cases with the respective targets expressed in human CICs [35].  
 In light of these findings, there is certainly a need to re-evaluate 
the evidence which supports the CIC model using assays that could 
allow for a better engraftment of human cancer cells. In 1989, Hill 
and Milas suggested that mouse tumors contained stem cells and 
that the number of these cells within the tumor could be an impor-
tant determinant of prognosis [36].  
 However, the first evidence of the existence of CICs/LSCs 
came from the seminal studies performed in human AML patients 
by Bonnet and Dick (see below) [37]. They demonstrated that leu-
kemic CICs were capable of serially transferring AML into an im-
munodeficient mouse host. AML CICs were hierarchically orga-
nized and originated from a HSC rather than a committed progeni-
tor cell. Leukemic CIC resided in the CD34+/CD38
-
/Lin
-
 compart-
ment (i.e. they are phenotypically similar to normal SCID repopu-
lating cells), although exceptions to this rule have been reported 
[38]. The existence of leukemia CICs has been subsequently dem-
onstrated in other malignant hematological disorders, including 
CML [39] and T-cell acute lymphoblastic leukemia (T-ALL) [40].  
 More than a decade after the identification of leukemic CICs, 
there is mounting evidence that CICs also exist in solid tumors. 
These include breast carcinoma [41], prostate carcinoma [42], pan-
creatic carcinoma [43], colon carcinoma [44], lung carcinoma [45], 
brain tumors (glioblastoma and medulloblastoma) [46], and hepato-
cellular carcinoma (HCC) [47]. However, compared with leuke-
mias, the issue of solid tumor CICs still remains in its infancy. 
 The so-called side-population (SP) is thought to be enriched in 
CICs. SP cells actively extrudes the nuclear acid-staining dye 
Hoechst 33342 owing to high expression on their plasma membrane 
of drug resistance transporters of the ABC family such as 
ABCB1and ABCG2, and can be easily identified by flow cytometry 
(See below) [48]. The enrichment of SP in leukemic CICs has been 
demonstrated in: multiple myeloma [49], T-ALL [50], AML [51], 
lung cancer [52], prostate cancer [53], breast cancer [54], glioblas-
toma [55], and HCC [56]. Intriguingly, it is emerging that in CICs, 
“stemness” genes are upregulated when compared with the main 
population. Accordingly, in the SP of liver cancer cell lines, the 
WNT pathway is highly expressed (See below) [57].  
INCREASED EXPRESSION OF PROTEINS INVOLVED IN 
DRUG RESISTANCE IN LEUKEMIA CICS 
 Although CICs from various types of cancer have the potential 
for self-renewal, they spend the majority of their time in the G0 
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phase of the cell cycle. This means that chemotherapeutic drugs, 
which act on cycling cell populations such as doxorubicin, are less 
effective on CICs than BCs [58]. Furthermore, the CICs are also 
often resistant to radiotherapy. The quiescent, non-cycling state of 
CICs may contribute to their resistance to conventional cancer 
treatments which target the rapidly proliferating cell. This quiescent 
nature of CICs may result in low rates of long-term remission and 
multi-drug resistance although, CICs also often display increased 
expression of drug transporter proteins.  
 Drug resistance can result from a plethora of mechanisms that 
include: decreased drug uptake, increased drug efflux, accelerated 
detoxification, defective apoptosis or altered expression of signal-
ing pathways [59]. A single biochemical abnormality listed above 
may not be sufficient for drug resistance; there may be more than 
one component involved. Often these different biochemical proper-
ties can interact, either additively or synergistically and result in an 
increased drug resistant phenotype. ATP-dependent drug efflux is 
often observed clinically and is frequently linked to the increased 
expression of ATP-binding cassette (ABC) transporter proteins 
[60]. This type of drug resistance occurs frequently in patients 
treated with drugs such as doxorubicin (a.k.a. Adriamycin). Patients 
with this type of drug resistance frequently develop “multi-drug” 
resistance as they become cross-resistant to drugs such as doxorubi-
cin, daunorubicin, paclitaxel, etoposide and others which can be 
transported by the same drug transporter [MDR1 (multi-drug resis-
tance-1 a.k.a., P-glycoprotein, Pgp), and multi-drug resistance asso-
ciation protein (MRP1) and others].  
 The ABC family of active drug transporters contains approxi-
mately forty-nine separate transmembrane proteins, many of which 
can function to efflux chemotherapeutic drugs [60-61]. Some of 
these proteins involved in transport are functional in diverse cell 
types and play critical roles in normal physiology by regulating the 
levels of a variety of nutrients and biologically active substances 
across cellular barriers. That is a key reason why it has been diffi-
cult to target “drug” transporters as they also regulate the levels of 
other types of molecules that are essential for normal physiology. 
The ABC family is divided into seven subfamilies: ABCA through 
ABCG. Several of these genes including ABCG1 and ABCB1 are 
expressed in immature CD34+CD38
-
 hematopoietic cell fractions 
and are down-regulated upon differentiation into the more mature 
CD34
+
CD38
+
 sub-population.  
 de Grouw and colleagues demonstrated that twenty-two ABC 
transporters were differentially expressed in AML CICs compared 
to AML BC. All the ABC transporters were expressed at lower 
levels in the more differentiated CD34
+
CD38
+
 cells in comparison 
to the less differentiated CD34
+
CD38
-
 cells [62]. ABCB1, ABCG2 
and ABCC1 are the three primary “multi-drug resistant” transporter 
genes that are expressed most frequently in tumor cells. Included in 
this sub-group are MDR1, BCRP (breast cancer resistance protein) 
and MRP1 [60]. These transporter proteins involved in drug efflux 
have been shown to confer drug resistance by mediating the active 
efflux of diverse anti-cancer drugs [63]. 
 MDR expression is often higher in patients with secondary 
leukemias as compared with those in primary disease states [64]. 
Several potential drugs have been developed in attempts to block 
and compete with Pgp mediated drug efflux. Unfortunately, most of 
these MDR1 inhibitors have not proven effective [60,62,65-67]. 
Second generation MDR modulators have also yielded similar re-
sults [67]. MDR1 is not the only transporter which can efflux cer-
tain commonly-used chemotherapeutic drugs. Novel drugs that 
inhibit multiple transporters and other modes of drug-resistance 
might be more effective. Upon examination of the expression of 
various ABC transporters, a high redundancy was observed in both 
normal and early AML cells which may contain the AML CICs 
[62]. That is, the AML cells may overexpress more than one trans-
porter which regulates the levels of a particular group of drugs. 
Current MDR modulators may be ineffective due to the expression 
of overlapping transporter proteins, which can efflux the same drug, 
thus making targeting of a single protein ineffective. Additionally, 
it is possible that irrelevant transporters were inhibited or there 
were pharmacokinetic interactions between the chemotherapeutic 
agent and the ABC transporter inhibitor. Third generation MDR 
modulators that are more powerful are being developed and exam-
ined in clinical settings [60] however, so far encouraging results 
have not been reported. Clearly the proteins involved in drug trans-
port could be key targets for elimination of CICs, however, it is also 
evident that their targeting will be difficult as there are functional 
overlaps between the different transporters and these transporters 
also play other essential roles in physiology. 
EXPLOITING INCREASED EXPRESSION OF DRUG 
TRANSPORTERS AND ALDEHYDE DEHYDROGENASE 
TO IDENTIFY LEUKEMIA CICS  
 The ability of CICs to efflux many drugs has been practically 
exploited in the isolation of CICs in different types of cancers. 
Many ABC transporters expressed in CICs efflux the fluorescent 
dyes Hoechst-33342 and rhodamine 123. This is in contrast to BCs, 
which retain the dyes. After Hoechst-33342 staining and flow cy-
tometric analysis, a large percentage of CICs have been shown to 
reside in the SP cells. These SP cells were found in the bone mar-
row of over 80% of AML patients [60]. Identification of SP cells 
was one of the first techniques used to identify CICs from various 
different types of cancers. 
 CICs isolated from various cancer types also often express ele-
vated aldehyde dehydrogenase activity (ALDH) and it is being used 
as a key marker for CIC identification [68]. AML patients who’s 
CICs express elevated ALDH have a poorer prognosis than patients 
which express lower levels of ALDH [68]. Targeting of ALDH is 
complicated as it likely plays important functions in many different 
tissue types, not just CICs and there are at least twelve different 
ALDH isoforms. 
A WELL STUDIED MODEL FOR CICS AND THERAPY—
CHRONIC MYELOID LEUKEMIA (CML) 
 In the following section, we will discuss CML as it is a well-
studied leukemia which has had significant advances in therapy in 
the past 15 years due to the discovery of the effective BCR-ABL 
inhibitor, Imatinib as well as additional second and third generation 
inhibitors. Furthermore, CML, unlike AML and many other can-
cers, has a unique chromosomal translocation, t (9;22), which is 
present in virtually 100% of CML patients [69]. As a result, part of 
the breakpoint cluster region (BCR) gene from chromosome 22 is 
fused with the c-ABL gene on chromosome 9. This abnormal "fu-
sion" gene generates a protein of 210-kDa (p210) or sometimes 
190-kDa (p190). 
 CML is characterized by the overproduction of mature myeloid 
cells. This leukemia is subdivided into three distinct phases: chronic 
phase, accelerated phase and blast crisis, which is phenotypically 
similar to AML. While AML CICs are biologically and functionally 
distinct compared to HSC, CML CICs are often phenotypically 
similar to normal HSCs. CML CICs cells are present in 
CD34+CD38
- 
cells and contain the BCRABL translocation present 
on what is historically referred to as the Philadelphia chromosome. 
CML patients have clonal expansion of hematopoietic cells that 
express the BCR-ABL proteins. Expression of BCR-ABL is essen-
tial for the sustained CML proliferation [70]. Current CML therapy 
is treatment with BCR-ABL kinase inhibitors. However acquired 
resistance to BCR-ABL kinase-inhibitor therapy can occur as well 
as a lack of sustained molecular remissions [63].  
 CML CICs are phenotypically CD90
+
, Thy1
+
 and Lin
-
. Blast 
crisis CML patients have higher levels of the progenitor pool
 
(CD34
+
Lin
–
 cells) than the other classes of CML patients. CML 
patients which are responsive to BCR-ABL targeted therapy, have 
fewer CD34
+
Lin
– 
cells in comparison to patients non-responsive to 
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BCR-ABL inhibitors. The -catenin pathway is overexpressed in 
patients resistant to BCR-ABL inhibitors [27,71] and will be further 
discussed below. The differences in response in patients resistant to 
BCR-ABL kinase inhibitors as compared to those not resistant im-
plies the acquisition of self-renewal capacity as well as other selec-
tive genetic changes in granulocyte–macrophage progenitors pre-
sent in the CML CICs [27]. These results demonstrate the complex 
differences between CML CICs and BCs. While both cell types 
display enhanced proliferative capacity in comparison to normal 
myeloid cells, they display different growth properties in the pres-
ence of BCR-ABL inhibitors, which may be due to the presence of 
discrete additional mutations in the BCRABL gene present in the 
CML CICs (see below) or selection as a result of treatment. 
 Some of the CML CICs exhibit elevated BCR-ABL expression 
and changes in levels of the cytokines interleukin-3 and granulocyte 
colony stimulating factor (which may serve autocrine stimulatory 
roles), and the drug transporters ABCB1/MDR1, ABCG2 and the 
transcription factor Oct-1 upon culture with reduced levels of 
growth factors [71]. Additional studies by Jiang et al., demonstrated 
that greater than seventy different BCRABL mutations were present 
in the progeny of cultured CML CICs [72]. This group has hy-
pothesized that CML patients possess CICs, which have pre-
existing BCRABL kinase mutations before the advent of BCR-ABL 
inhibitor therapy; hence the patients already have some resistant 
CML CICs. As the CML CICs proliferate slowly, the patient may 
be initially responsive to therapy, then given time, CML CICs that 
are resistant to BCR-ABL inhibitors emerge (see discussion of 
mathematical models for CML presented below). This karyotype 
evolution of resistant cells from pre-existing CML CICs, which 
already have mutations in BCRABL, is a lingering problem in BCR-
ABL-directed therapy (15). Since CML CICs, like other CICs pro-
liferate slowly, or are in a quiescent-like state, some investigators 
have proposed that a means to target these cells is to stimulate their 
proliferation and then treat with BCR-ABL inhibitors [73-74]. 
However, this therapeutic approach will only be appropriate if the 
CML CICs do not contain the T315I BCRABL mutation or a similar 
mutation, which confers resistance to many BCR-ABL inhibitors. 
MATHEMATICAL MODELING PROVIDES EVIDENCE 
FOR CML CICS 
 Upon careful mathematical analysis of the CML incidence data 
and reappearance of the disease after discontinuation of therapy, it 
has been predicted that there are pre-existing CML CICs which are 
already resistant to BCR-ABL inhibitors such as Imatinib [75-78]. 
Basically upon analysis of the decrease in BCR-ABL mRNA tran-
scripts upon and during the course of Imatinib treatment, a decrease 
to a low, constant level of BCR-ABL mRNA transcripts was ob-
served as long as the drug Imatinib was effective, however once the 
patient was taken off Imatinib therapy, there was a dramatic, and 
rapid rebound in the level of BCR-ABL mRNA transcripts which 
actually may exceed the initial levels of BCR-ABL mRNA tran-
scripts. These results suggest the existence of CML CICs in the 
CML patients which were not eliminated by the Imatinib treatment. 
In addition, this model provides an explanation of the biphasic de-
crease of the BCR-ABL transcript upon initial therapy with 
Imatinib. Initially Imatinib quickly eliminates the terminally differ-
entiated leukemic cells with an average lifespan of approximately 
twenty days which leads to a rapid decrease in the levels of BCR-
ABL mRNA transcripts. However, after elimination of these differ-
entiated cells, the less mature leukemic progenitors with an average 
lifespan of 125 days under Imatinib therapy are responsible for the 
slower but continued decrease of the BCR-ABL transcripts. The 
immature CML CICs are not sensitive to Imatinib, and expand 
gradually over time at a slow rate and are responsible for a rapid 
rebound of the leukemic burden upon cessation of Imatinib treat-
ment which can exceed the initial level. Furthermore, if there are 
mutations present in the BCRABL gene which confers resistance to 
Imatinib, the emergence of this clone(s) appears and levels of BCR-
ABL mRNA transcripts increase even in the presence of Imatinib, 
again arguing for the presence of CML CICs in the CML leukemia 
patient. The models of Michor et al. also describe well the higher 
incidence of mutations in patients who receive therapy at a later 
stage of the disease. In these patients, the increased pool of CML 
CICs has a higher stochastic probability of mutations which then 
lead to a rapid expansion of resistant progenitors and treatment 
failure. 
 The quiescent nature of CML CICs may be responsible, in part, 
for the failure of Imatinib treatment to result in their total elimina-
tion. CML CICs may enter a dormant, Imatinib-resistant state or in 
some cases enter a proliferative Imatinib-sensitive state. Also CML 
CICs express higher levels of Pgp. Imatinib is a substrate for Pgp, 
thus with drug resistant CML CICs, Imatinib will not be an effec-
tive drug. Mathematical models, with various growth related pa-
rameters, have been proposed to explain the asymmetrical stem cell 
replication; however the biochemical mechanisms responsible for 
the asymmetry of CIC division are not well understood. Mutations 
occurring in the BCRABL gene are commonly thought to occur 
before disease onset and treatment, thus they are not believed to be 
responsible for the quiescence nature of the CML CICs. Cells con-
taining mutant BCRABL genes may emerge later, due to the elimi-
nation of the cells with the wild type (WT) BCRABL gene upon 
Imatinib treatment. This model implies that the cells with the mu-
tant BCRABL genes may not proliferate as well initially as the cells 
with the WT BCRABL gene. On the other hand, conflicting data 
indicate, that these mutations may confer a growth advantage, even 
without Imatinib treatment [79-80]. Clearly these models need fur-
ther investigation. What are the key messages that we have learned 
from CML CICs? Many therapy-resistant CML CICs may already 
exist in the CML patient with key BCRABL mutations before ther-
apy. After cessation of therapy these resistant CML-CICs may 
emerge and expand, perhaps in part due to the BCR-ABL treatment 
eliminating the CML BCs which were responsive to the therapy. 
INTERACTIONS OF BCR-ABL WITH DOWNSTREAM 
SIGNALING PATHWAYS LEADING TO IMATINIB RE-
SISTANCE--POTENTIAL NOVEL TARGETS FOR THER-
APY 
 BCR-ABL induces multiple signaling pathways, that is proba-
bly why it is such a “potent” oncogene. Also it must be remembered 
that BCR-ABL is not a normal protein in the cell, it is a chimeric 
protein encoded by the abnormal BCRABL chromosomal transloca-
tion. BCR-ABL can activate the RAS/RAF/MEK/ERK, PI3K/Akt, 
p38MAPK, JNK, FAK, SRC and RAC signaling cascades [69, 80]. 
BCR-ABL can also interact with SRC-family kinase HCK which 
can lead to STAT5A activation that is JAK kinase-independent. 
This may be an important factor in the resistance of cells to 
Imatinib therapy (see below for section on SRC kinases) and also 
why it is appropriate to treat certain CMLs with SRC inhibitors 
such as Dasatinib. An important signaling family induced by BCR-
ABL is the RAC family of GTPases which was summarized in a 
recent review [80]. An overview of some of the signaling pathways 
activated in leukemic CIC is presented in Fig. (1). Also presented in 
this figure are the sites that small molecule inhibitors and antibodies 
may act. 
 RAC is a multi-gene family which consists of RAC1, RAC2 and 
RAC3. RAC1 and RAC3 are ubiquitously expressed while RAC2 is 
expressed predominately in hematopoietic cells. BCR-ABL also 
interacts with RHO GTPases including RAC, RHO and CDC42. 
RAC-1, RAC-2 and to a lesser extent RAC-3 are detected at hyper-
activated levels in HSCs and CML CICs. RAC-1 and RAC-2 coop-
erate with BCR-ABL and induce a myeloproliferative disease of 
HSC origin. Deficiency of RAC1 and RAC2 in specific knock-out 
mice reduced the severity of BCR-ABL-mediated transformation 
and prolonged survival was observed [81-82]. RAC-3 may play an 
important role in the cancer development in the BCRABL, Rac-
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1/Rac-2-deficient mice. These results suggest an important role for 
RAC GTPase in BCR-ABL-mediated CML CIC generation as well 
as in normal HSC functions. The RAC GTPases and RAS may be 
important in the induction of STAT5 which may be abnormally 
activated by various mechanisms, including an autocrine mecha-
nism in Imatinib-resistant CML [83].  
 RAC proteins play key roles in the retention of murine HSC 
and may be an appropriate target to eliminate CICs [82,84]. The 
effects of an experimental RAC inhibitor (NSC23766) on HSC 
mobilization have been examined [82]. This inhibitor increased 
HSC mobilization, suppressed RAC activation and downstream p21 
activated protein kinase (PAK) activation. NSC23766 also inhibited 
the growth of BCR-ABL- transformed cells, even those containing 
the Imatinib-resistant T315I mutation [85]. This RAC inhibitor may 
mobilize CML CICs from their niche and thus inhibit the stem cell 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Interactions between BCR-ABL, RAC, RAS/RAF/MEK/ERK, RAS/PI3K/PTEN/mTOR and Wnt/ -Catenin Pathways that Result in the 
Regulation of Protein Translation and Gene Transcription in Leukemia CICs and Potential Sites of Interaction by Small Molecule Inhibitors. The 
Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/mTOR pathways can affect protein translation by complex interactions regulating the mTORC1 and mTORC2 
complexes. GF stimulation results in GFR activation which can activate the Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/mTOR, JAK/STAT as well as other 
pathways. Chromosomal translocation such as BCR-ABL can activate these pathways as well as others including RAC and SRC. AKT can phosphorylate and 
inhibit the effects of GSK-3 , TSC2 and PRAS-40, which result in mTORC1 activation. ERK and PDK1 can phosphorylate p90Rsk1, which in turn can phos-
phorylate and inhibit TSC2. AKT-mediated phosphorylation of GSK-3  also affects the WNT/ -catenin pathway and epithelial mesenchymal transition 
(EMT). SRC also has effects on activation of the WNT/ -catenin pathway. Rapamycin targets mTORC1 and inhibits its activity and also results in inhibition 
of downstream p70S6K. The effects of rapamycin are complex as long term administration of rapamycin may prevent mTOR from associating with mTORC2 
and hence full activation of AKT is prevented. However, rapamycin treatment may result in activation of PI3K, by inhibiting the effects of p70S6K on IRS-1 
phosphorylation which results in PI3K and AKT activation. Also rapamycin treatment may result in the activation of ERK in some cells, presumably by inhi-
bition of the p70S6K mediated inhibition of IRS1. These later two effects of rapamycin could have positive effects on cell growth. Inhibition of PDK-1 activ-
ity can also result in activation of mTORC1, presumably by suppression of p70S6K and hence inhibition of IRS1 effects on PI3K activity. The PTEN, TSC1 
and TSC2 tumor suppressor genes all converge on the mTORC1 complex to regulate protein translation. RHEB is a small G protein important for the regula-
tion of mTORC1 & 2 and is negatively regulated by TSC2 and is also subject to farnesylation. Thus the RAS/RAF/MEK/ERK and 
RAS/PI3K/PTEN/Akt/mTOR pathways can finely tune protein translation and cell growth by regulating mTORC1. Rapamycin can have diverse effects on 
these processes. Also these pathways can interact with the WNT/ -catenin pathway which is important in developmental processes, EMT and CICs. Upon 
activation of the WNT pathway, -catenin forms a complex with Bcl-9, PYGO, plakoglobulin and TCF/LEF which result in the transcription of critical genes 
including cyclin D1, c-Myc, SALL4 and PPAR . The sites where key inhibitors targeting molecules are important in these pathways are indicated in black 
octagons with white lettering. FT = farnesyl transferase inhibitor.  
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properties of these cells. Hence, this inhibitor, unlike others such as 
Imatinib, may effectively target the CML CICs. 
ROLE OF SRC FAMILY KINASES IN CML AND ALL CICS 
 Imatinib has proven highly effective in treatment of CML, 
however, Imatinib, by itself, will not cure CML. This is often due to 
the development of resistance in the CICs (as described above). 
SRC and other signaling pathways are involved in Imatinib resis-
tance [86-87]. SRC family kinases are activated by BCR-ABL and 
inhibition of BCR-ABL by Imatinib may not result in the complete 
inhibition of SRC-family kinases. BCR-ABL is known to activate 
at least three SRC-family kinases (LYN, HCK and FGR) which are 
required for the development of BCR-ABL-mediated proliferation 
of preB-acute lymphoblastic leukemia (ALL), but not myeloid pro-
genitor cells [88]. However, all three of these SRC-family kinases 
are activated by BCR-ABL in myeloid cells. BCR-ABL may di-
rectly interact with at least two SRC-family kinases (LYN and 
HCK) and alter their activities [89-90]. By performing genetic stud-
ies it was demonstrated that LYN, HCK and FYN are required by 
BCR-ABL to induce CML to progress to lymphoid blast crisis in 
mice injected with BCR-ABL-transduced bone marrow [86]. 
 As stated previously in this review, some CML CICs carrying 
BCRABL mutations such as T315I are resistant to Imatinib, 
Dasatinib and other BCR-ABL inhibitors. However, in the studies 
by Hu et al., [86], they demonstrated that while BCR-ABL kinase 
inhibitors prolong the survival of CML mouse models, they do not 
completely eliminate CML CICs. In these studies, the structures of 
the BCRABL genes in CML CICs were determined and they did not 
have the BCRABL T315I mutation. These results strongly indicate 
that other mutations, can be involved in CML development and that 
Imatinib and Dastinib are not adequate to completely eliminate the 
CML CICs. 
 Alternatively, other genetic mutations occurring in blast crisis 
CML may contribute to the persistent activation of SRC. Mutations 
at other genes including, INK4a, RB and TP53 among others are 
involved in CML progression [91-93]. Loss of the ARF gene en-
hances tumorigenicity of BCRABL-transformed cells and limits the 
response to Imatinib in BCR-ABL-induced B-ALL mice [94]. Stud-
ies by Hu et al., [86] have demonstrated that the progression to 
lymphoid blast crisis requires activation of SRC family kinases and 
the SRC kinase inhibitor Dasatinib was more effective than 
Imatinib in preventing B-ALL, however, eventually the disease 
reoccurred. Furthermore, while Dasatinib treatment prolonged the 
life of the CML mice, it did not eradicate CML CICs cells. The 
authors have therefore suggested that an additional component of 
BCR-ABL-expressing CML CICs must be suppressed for complete 
eradication of the disease. Furthermore, certain BCRABL mutations 
such as T315I are resistant to Imatinib, Dasatinib and other BCR-
ABL inhibitors. Interesting, Aurora kinase inhibitors (VX-680) 
have shown promise in inhibiting Imatinib-resistant BCRABL 
T315I-transformed cells [95-96].  
 SRC kinases may induce the WNT/ -catenin and RAF/MEK/ 
ERK signaling pathways which result in LEF/TCF activation [97-
98]. Activation of these and other signaling pathways may contrib-
ute to the survival of CICs (see below). 
INVOLVEMENT OF THE WNT/ -CATENIN SIGNALING 
PATHWAY IN LEUKEMIA CICS 
 The WNT signaling pathway plays a critical role in self-
renewal of HSCs and its dysregulation may be involved in CIC 
generation. There are approximately 20 WNT genes in the human 
genome and they encode lipid-modified secreted glycoproteins 
[99]. WNT induces cell signaling to a receptor complex consisting 
of a Frizzled family receptor and a co-receptor of the LDL-receptor 
related protein family, usually LRP5 or LRP6. This can result in the 
destabilization of the multiprotein destruction complex (MDC) and 
the subsequent stabilization of -catenin. -catenin normally has a 
very short half life. In the absence of WNT, -catenin is normally 
phosphorylated by components of the MDC including: axin, ade-
nomatous polyposis coli (APC), glycogen synthase kinase 3  
(GSK-3 ) and casein kinase 1 (CK1). When -catenin is phos-
phorylated by these kinases, it is targeted for proteasomal degrada-
tion Fig. (1).  
 In contrast, if cytoplasmic -catenin is stabilized by WNT sig-
naling (that is not phosphorylated by the MDC complex); it mi-
grates to the nucleus and replaces the groucho-related repressors 
present on certain genes. -catenin in the presence of the accessory 
proteins BCL-9, PYGO (pygopus) and the TCF/LEF (T-cell fac-
tor/lymphocyte-enhancer-binding factor) forms a complex which 
results in transcription of important growth promoting genes such 
as CMYC and CYCLIN-D1 (CCND1). Furthermore, TCF/LEF can 
result in an increase in SALL4 expression which is an oncogene that 
can bind to -catenin and enhance its activity. Plakoglobin is an-
other important component of WNT signaling. It is a co-inducer of 
TCF/LEF transcriptional activation and stimulates the transcription 
of CYCLIN-D1, c-MYC and perxosome proliferator-activated re-
ceptor-delta (PPAR ). Plakoglobulin expression is enhanced by 
certain AML fusion proteins. The WNT pathway is frequently dys-
regulated in AML [27].  
 The WNT pathway is regulated by many different inhibitors 
which have been shown to have important roles in oncogenesis. 
These interactions are well described in the above mentioned com-
prehensive review by Mikesch et al., [99]. Some key inhibitors 
include members of the Dickkopf (DKK) family which interact 
with LRP5/6 and prevent the transmission of signals from the Friz-
zled-LRP complex. The WNT inhibitor factor 1 (WIF-1) is another 
inhibitor of the WNT pathway. It is an extracellular protein which 
binds to WNT, thereby inhibiting the WNT pathways [100]. The 
promoter region of WIF1 is hypermethylated in many APLs and 
associated with a poorer disease free three year survival rate than in 
patients without WIF-1 promoter methylation [101].  
 Importantly, this pathway has been shown to have critical roles 
in self renewal of HSC and CICs [102-104]. WNT expression in-
hibits the differentiation of HCS [104-105]. Overexpression of axin, 
a component of the MDC, inhibits WNT signaling and in turn this 
results in decreased growth of HSC [102]. Constitutive overexpres-
sion of activated -catenin increased the frequency of HSC and 
prevented their differentiation [102].  
 Specific deletion of -catenin (CTNNB1) in hematopoietic line-
ages in mice did not prevent the formation of HSC, however, the 
HSC were deficient in long-term growth and maintenance [103]. 
The target(s) for CML CICs and BCR-ABL-transformation were 
greatly reduced while the induction of ALL occurred fairly nor-
mally. These and other results suggest that ALL may arise from a 
more mature stem cell committed to the B cell lineage. Conditional 
deletion of -catenin (CTNNB1) decreased the self-renewal ability 
of CML CICs. Thus -catenin was necessary for the increased self-
renewal capacity conferred by the introduced BCRABL oncogene 
on the target stem cells to permit transformation to proceed along 
the myeloid lineage. The authors demonstrated that BCR-ABL 
phosphorylation was decreased in the -catenin-deficient mice 
which also resulted in lower levels of phosphorylated STAT5a. 
BCR-ABL and -catenin form a complex and the authors have 
suggested that this complex may stabilize BCR-ABL [106]. Reduc-
tion of the BCR-ABL: -catenin complex could result in a decrease 
in the phosphorylation of BCR-ABL targets such as STAT5a and 
decrease CML self renewal and disease progression. These impor-
tant results provide further evidence of the role of -catenin and the 
WNT pathway in normal HSC as well as CML CICs and demon-
strate the stem cell origin of CML but not ALL. WNT signaling 
may be critical for BCR-ABL stability and the maintenance of 
CML CICs. The WNT pathway may serve to differentiate CML and 
ALL. The successful development of WNT inhibitors may serve to 
augment the ability of BCR-ABL inhibitors to eradicate CML. 
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WNT inhibitors are being developed by several pharmaceutical and 
biotechnological companies; however, there do not appear to be any 
peer-reviewed papers documenting their effectiveness. 
 Not unexpectedly, the WNT signaling pathway interacts with 
other signaling pathways including Notch, sonic hedgehog and 
PI3K/AKT [106-108]. Increased FLT-3 signaling in AML patients 
with mutations/amplifications of FLT3 may result from AKT medi-
ated phosphorylation and inactivation of GSK-3  which results in 
higher levels of WNT signaling and stabilized -catenin [109]. 
Alternatively, Frizzled-4, a WNT receptor, is induced by certain 
FLT3 mutations which lead to increased -catenin levels that result 
in augmented TCF/LEF activity and c-MYC transcription [110-
111]. 
INTERACTIONS BETWEEN CICS AND THEIR MICRO-
ENVIRONMENT AND POTENTIAL MOLECULES FOR 
TARGETING 
 Whether CICs also depend on their particular niche for self-
renewal is currently
 
unclear. While there are clear differences be-
tween normal
 
stem cells and CICs, there are also striking similari-
ties. Some molecular mechanisms that
 
enable self-renewal in nor-
mal stem cells may exist in CICs. 
 Indeed, both normal HSC and leukemic CICs depend on stro-
mal cell derived factor-1 (SDF-1)-mediated
 
CXCR4 (CXC 
chemokine receptor-4 which is specific for SDF-1) signaling for 
homing and mobilization [112]. WNT-induced
 
-catenin signaling 
has been implicated in the maintenance
 
and expansion of murine 
HSCs, whereas inhibition of the
 
-catenin pathway severely im-
paired
 
the self-renewal capacity of CML CICs [27,102,113]. The 
adhesion of normal CD34
+
 stem/progenitor
 
cells to bone marrow 
stroma and fibronectin is mediated by the
 
integrins VLA-4 and 
VLA-5, and a similar role
 
is fulfilled by integrins in leukemic cells 
[114-115]. Thus, many of the molecules that mediate the interaction
 
between stem cells and the bone marrow niche are utilized by
 
both 
normal HSC cells and CML CICs. 
 Whether the leukemic CIC needs collaborative genetic hits to 
improve their interactions with the extrinsic stem cell niche remains
 
an intriguing question. One possibility is that CICs migrate more 
when compared with normal HSCs that
 
allowing the CICs to escape 
growth inhibition or quiescence promoting
 
signals induced by os-
teoblasts and stromal cells in the niche.
 
Many membrane-associated 
ligands are normally present
 
in the niche, and they can be cleaved
 
by matrix metallo-proteinases (MMPs). MMPs and their tissue 
inhibitors (TIMPs) are important in the progression and invasive-
ness of many malignant disorders. The expression of MMPs such as 
MMP9 is often
 
elevated in AML blasts [116]. MMPs may increase 
the soluble concentrations of activated ligands to enable leukemic 
CIC self-renewal or expansion outside the
 
niche. Therefore, the 
level of marrow MMP-9 may be a useful surrogate marker for 
monitoring disease status in AML and it was proposed as a poten-
tial prognostic factor. Targeted inhibition of MMPs may inhibit 
CIC expansion and may prove useful in leukemia therapy.
 
 Targeting CD44 with a monoclonal antibody could suppress 
both AML and CML progression and induce differentiation [117-
119]. The monoclonal anti-CD44 Ab may disrupt interactions be-
tween the CICs and the bone marrow niche. RAC inhibitors may 
also disrupt these interactions and mobilize LSC (see below). 
SUPPRESSING CICS: TARGETING THE PI3K/PTEN/ 
AKT/MTOR PATHWAY 
 The PI3K/PTEN/Akt/mTOR pathway, and specifically PTEN 
levels, may be critical for the development of CICs
 
[120-137].  
 The concept that the PI3K/PTEN/Akt/mTOR pathway serves as 
a therapeutic target in leukemia CICs is beginning to emerge. CICs 
have unique properties as they can be both quiescent and also resis-
tant to chemotherapeutic and hormonal based drugs. However, 
under certain conditions, they resume proliferation and hence could 
be potentially susceptible to PI3K, AKT or mTOR inhibitors.  
 The PTEN gene exerts effects on CICs, especially in hema-
topoietic and breast cells. In conditional PTEN knock-out mice, 
upon inactivation of PTEN, there was a transient increase in hema-
topoietic CICs and a myeloproliferative disease develops and the 
mice subsequently developed leukemia after 4-6 weeks [120]. If the 
mice were treated with the mTOR inhibitor rapamycin, the mye-
loproliferative disorder and leukemia were prevented. The initial 
leukemic CICs that arose after conditional PTEN deletion by them-
selves were not able to induce leukemia upon transfer into SCID-
recipient mice, but if the leukemic CICs were derived from the 
PTEN-conditional mice that had developed leukemia, they were 
able to transfer leukemia to the SCID-recipient mice, which could 
be prevented by rapamycin treatment. Also the normal HSC from 
the PTEN-conditional knock-out mice repopulated the hema-
topoietic cell component of irradiated mice treated with rapamycin 
indicating that it was possible to selectively eliminate leukemic 
CICs. However, rapamycin treatment did not eradicate the PTEN-
deficient leukemia CICs after leukemia onset. 
 PTEN plays critical roles in regulating cell cycle progression in 
HSC and other cells. PTEN influences the decision of whether the 
cells remain in quiescence (G0) or enter G1 and also controls the 
subsequent speed of proliferation [128]. Importantly PTEN influ-
ences hematopoietic differentiation and PTEN-deficiency blocks 
differentiation of B lymphoid stage resulting in an increase in the 
presence of myeloid and T cells but a decrease in cells of the B-
lineage.  
 Additional studies have identified some of the genes which can 
interact with PTEN deletion to influence leukemogenesis [130]. The 
authors demonstrated that PTEN-deletion induced the expression of 
p16
Ink4a
 and TP53 in the HSC and p19
Arf 
and TP53 in other hema-
topoietic cells. Functional TP53 suppressed leukemogenesis in 
PTEN-deficient mice and also promoted HSC depeletion. While 
p16
Ink4a
 also stimulated HSC depletion, it had a limited role in sup-
pressing leukemia development. In contrast, p19
Arf 
strongly sup-
pressed leukemia development but did not decrease HSC levels. 
The authors demonstrated that in the PTEN-mutant mice, secondary 
mutations inhibited the tumor suppressor response. Therefore in the 
leukemic clones that arose in these PTEN-deficient mice, mTOR 
activation depleted HSC by a tumor suppressor response which was 
inhibited by secondary mutations. These authors did not observe a 
role for reactive oxygen species (ROS) in the depletion of HSCs in 
PTEN-deficient mice. In contrast, other studies have suggested 
roles for ROS in depletion of TSC1-deficient HSCs [131]. In these 
studies, TSC1 depletion led to mTOR activation, exit from quies-
cence, increased proliferation but resulted in exhaustion of HSCs 
without the development of leukemia. 
 Other genes in this pathway also have been shown to have ef-
fects on HSC depletion. TSC1-deficient mice result in increased 
PI3K/PTEN/Akt/mTOR signaling which leads initially to increased 
HSC cell cycling and mobilization then to progressive depletion 
and defective long term repopulation [132]. These authors also 
demonstrated that TSC1 regulation of HSC mobilization is also 
effected by mTORC1-independent mechanisms and that one of the 
genes involved is the actin-bundling protein FSCN1 (fascin). Fascin 
is believed to be an important mTORC1-independent mediator of 
the effects of TSC1 on the regulation of HSC mobilization. FSCN1 
plays important roles in controlling cytoskeleton organization and 
motility and is upregulated in many human cancers. Fascin pro-
motes cell migration and invasion [133]. TSC1 regulation of fascin 
may play important roles in the dissemination of leukemia CICs. 
This is an interesting observation as in solid tumor CICs; a frequent 
observation is the formation of sphere-like cells (e.g., mammos-
pheres) and masses. FOXO is also an important regulator of HSC 
homeostasis. FOXO is essential for long-term HSC regeneration. 
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FOXO regulates quiescence and survival in response to oxidative 
stress [134-135].  
SUPPRESSING CICS: TARGETING PML 
 Targeting of PML also leads to increased HSC cycling and to 
mTOR-mediated HSC depletion [136]. The PML gene is involved 
in the t(15:17) chromosomal translocation found in acute promye-
locytic leukemia (APL). PML encodes a protein which localizes to 
PML nuclear bodies. PML is a tumor suppressor and controls many 
processes including apoptosis, proliferation and senescence. PML is 
reported to have diverse biological functions and is a negative regu-
lator of the AKT/mTOR pathway at multiple levels including op-
posing the nuclear function of AKT, repressing mTOR activity by 
inhibition of RHEB/mTOR in hypoxia and regulating PTEN local-
ization through modulation of a deubiquitination network [128]. 
PML is highly expressed in HSCs and there are more PML nuclear 
bodies in the HSC than in the committed cell populations. PML 
expression decreases as the HSC differentiate. PML also has conse-
quences on the outcome of CML. CML blasts express high amounts 
of PML which is regulated at the transcriptional level. PML loss or 
lower expression predicts a better prognosis in CML [128,137]. 
Recently it has been shown that PML is a negative regulator of 
mTOR [137]. PML is important in HSC maintenance and PML
-/-
 
HSC display increased cycling compared to HSC from normal 
mice, but the PML
-/- 
HSC lack long-term repopulating capacity 
which is likely due to defective maintenance of quiescence. Condi-
tional ablation of PTEN in the hematopoietic system of mice drives 
exit from quiescence, exhaustion of normal HSC, and generation of 
leukemia CICs via activation of the PI3K/Akt/mTOR pathway. 
Likewise loss of PML enhances the cycling pool of HSCs though 
mTOR activity. However, an important difference between PML
-/-
 
and conditional ablation of PTEN is that PML
-/-
 mice do not de-
velop leukemia, whereas in mice where PTEN is conditionally-
ablated, leukemia develops [128]. The exit from quiescence is more 
profound in leukemia CICs from PML
-/-
 mice than in HSC from 
PML
-/-
 mice, indicating a potential difference which could be ex-
ploited for therapy. Rapamycin opposes leukemogenesis in PTEN-
conditional knock-out mice and restores normal HSC function. In 
contrast, rapamycin restores leukemia CIC maintenance in the 
PML
-/-
 model. 
 PML expression is high in leukemia CICs [136]. PML is very 
important for leukemia CIC maintenance. Leukemia CICs from 
PML
-/-
 mice were generated by infection with a retrovirus encoding 
BCR-ABL. Similar to HSC isolated from PML
-/-
 mice, leukemic 
CICs from PML
-/-
 mice undergo intensive cell cycling, but dis-
played reduction of long-term transfer of CML disease (in the third 
serial bone marrow transplant), failed to generate minimal residual 
disease and impairment of leukemia CIC maintenance.  
 Arsenic trioxide (As2O3) selectively targets PML for degrada-
tion. As2O3 specifically targets KSL (c-Kit
+
, Sca-1
+
, Lin
-
) cells and 
reduced their colony forming ability but did not affect KSL cells 
isolated from PML
-/-
 mice. 
 Increased mTOR activity was observed in HSC prepared from 
PML
-/-
 vs. WT mice. Rapamycin treatment restored the colony 
forming ability of PML
-/-
 HSC and rescued the phenotype of PML
-/-
 
HSCs and leukemia CICs [136]. Rapamycin increased the quies-
cence of PML
-/-
 HSCs. PML has an important role in maintenance 
of HSCs by repressing mTOR activity. Rapamycin also had effects 
of PML
-/-
 leukemia CICs. It restored their ability in long term col-
ony formation assays. PML downregulation eliminates leukemia 
CICs. 
 As2O3 reduced PML levels in leukemic CICs and decreased the 
number of quiescent CIC in the absence of the induction of apopto-
sis [128,136-137]. Consistent with these results, the long-term 
maintenance of the CIC was dramatically suppressed. The authors 
examined the effects of cytosine arabinoside (Ara-C) and As2O3 on 
leukemia CICs. They hypothesized that interventions that increase 
the cycling of quiescence CIC might enhance their death by che-
motherapeutic agents. The combined treatment resulted in eradica-
tion of the CICs even after 4 weeks after termination of treatment 
and long term repopulating assays could not detect the presence of 
CICs or the presence of minimal residual disease. 
 Importantly the authors demonstrated that the HSC and leuke-
mic CICs display some important differences. Namely there were 
fewer quiescent cells in BCR-ABL- expressing CICs than in control 
KSL HSC, suggesting that the reservoir of quiescent cells is higher 
in normal HSC than in CICs [128,136-137]. Furthermore the 
As2O3-induced exit from quiescence was more profound in the 
CICs than in the HSC. The authors also confirmed some of these 
important observations on CICs and HSCs isolated from human 
CML patients and normal volunteers respectively. These studies 
indicate the potential therapeutic approaches of combining PML-
reducing drugs and chemotherapeutic drugs for certain leukemia 
therapies. 
 The PI3K/PTEN/Akt/mTOR pathway may mediate HSC activ-
ity through AKT/FOXO instead of mTOR [134-135]. PML may 
oppose mTOR as well as AKT/FOXO and hence is a critical regula-
tor of HSC and leukemia CICs. 
EFFECTS OF AGE OF CICS ON MALIGNANT POTEN-
TIAL 
 Recently is has been shown in certain animal models that there 
is a correlation between the age of the induction of leukemia and 
the rapidity of development of the leukemia [138]. In these studies 
it was determined that the age of the recipient mice did not alter the 
potential for leukemia after injection of BCRABL-transformed 
BaF/3 cells, namely, both young and old mice developed leukemia 
at approximately the same time. However, in a conditional 
BCRABL-mouse model (CombitTA-BCR-ABLp190) where the 
expression BCR-ABL could be regulated by controlling the pres-
ence or absence of doxycline (tetracycline-repressor system), it was 
observed that leukemia (B-ALL) was more rapid when BCR-ABL 
was induced by removing doxycline from the drinking water at 
either 12 or 20 months of age than when BCR-ABL was induced in 
4 months of age. This may result from the selection of CICs with a 
more potential malignant phenotype in the older mice. Alternatively 
there may be more complimenting mutations in the CICs present in 
older mice which can interact with BCR-ABL to result in more 
aggressive CICs than in the CICs present in younger mice. 
CANCER INITIATING CELLS IN SOLID CANCERS  
 CICs have been identified in many different solid tumors in-
cluding, breast, prostate, colon, hepatocellular carcinoma, pancre-
atic, glioblastoma, melanoma and others [122-129, 139-143]. Some 
of these CICs (e.g., colorectal CICs) express one or multiple cell 
surface markers associated with stemness such as CD122, CD44, 
CD24, CD29, CD166 and Lgr5 [139]. The targeting of certain of 
these molecules may eliminate CICs [139]. The PI3K/PTEN/ 
Akt/mTOR Pathway has been shown to be important in multiple 
cancer types including breast cancer [121-122, 143-144]. Targeting 
this pathway may be an appropriate approach to eliminate CICs.  
CONCLUSIONS 
 CICs are thought to be the essential fraction of the tumor that is 
responsible for the integrity of the tumor. That is, the CICs can re-
establish the tumor after removal of the original tumor by chemo- 
or radio-therapy or surgical approaches. Experimentally, the CICs 
can transfer the tumor more effectively to recipients than the bulk 
of the more differentiated tumor mass. CICs differ from BC as the 
CICs have retained certain essential properties of stem cells and the 
CICs are normally dormant or slowly replicating while the BCs are 
more rapidly proliferating. Importantly the CICs can undergo dif-
ferentiation and give rise to the differentiated cells present in the 
original cancer as well as therapy-resistant cells. Therapy-resistant 
1792    Current Pharmaceutical Design, 2012, Vol. 18, No. 13 McCubrey et al. 
cells may result from mutations that occur in the CICs during the 
original cancer treatment, or they may be a sub-population of CICs 
which already contain the mutation and hence are selected for dur-
ing the therapy. The key dilemma with CICs is that they are often 
refractory to most common anti-cancer approaches such as chemo-, 
radio-, or hormone based therapies. However, CICs may show 
some sensitivity to certain novel therapies. Development of novel 
approaches to target CICs could significantly enhance cancer ther-
apy. In summary, the specific therapeutic targeting of leukemia 
CICs is a field in its infancy. The tumor cell microenvironment or 
niche may also be an important therapeutic target and Rac inhibi-
tors as well as various anti-integrin antibodies may be appropriate. 
Recently the WNT- -catenin and PI3K/PTEN/Akt/mTOR and PML 
pathways have been shown to be important in leukemia CICs. 
Targeting these pathways may enhance leukemia therapy. As we 
learn more about the various leukemic CICs, it undoubtedly will 
result in novel ways to treat leukemias. Certain natural products 
commonly used in traditional medicine may prove effective in 
interacting with chemotherapeutic drugs to target leukemia CICs. 
Drugs such as As2O3 may target critical proteins involved in CIC 
proliferation. Leukemia CICs pose challenges to classical 
chemotherapeutic approaches due their slow rate of proliferation 
and quiescent-like properties. Additionally, the increased 
expression of ABC transporter proteins and various cell-signaling 
pathways further adds complexity to the situation. However, their 
pivotal role in the overall control and propagation of a variety of 
cancers and some initial responses to various inhibitors and 
treatments shows their therapeutic potential. Ultimately, previous 
research has shown that we must be clever and multi-faceted in our 
approach to design therapies, which may be effective in selectively 
eliminating these leukemia CICs. 
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